ADC Initial Results from Investigator-Initiated Phase 2 Lymphoma Trial

 Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate

https://www.globenewswire.com/news-release/2023/12/12/2794525/0/en/ADC-Therapeutics-Announces-Initial-Results-from-Investigator-Initiated-Phase-2-Clinical-Trial-Evaluating-ZYNLONTA-in-Combination-with-Rituximab-in-Patients-with-Relapsed-Refractory.html